Figure 4b.
Overall Survival (OS) by Disease Refractory or Not to Previous Bortezomib Therapy (LDC=Low-dose Carfilzomib; Arm 1, HDC=High-dose Carfilzomib; Arm 2); vertical line marks 11 months of active treatment on either arm of the trial.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.